1,1-dimethylethyl 4-{3-[6-amino-2-(methyloxy)-3-pyridinyl]-3-oxopropyl}-1-piperidinecarboxylate | 557106-91-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1,1-dimethylethyl 4-{3-[6-amino-2-(methyloxy)-3-pyridinyl]-3-oxopropyl}-1-piperidinecarboxylate
• 英文别名: Tert-butyl 4-[3-(6-amino-2-methoxy-3-pyridinyl)-3-oxopropyl]-1-piperidinecarboxylate；tert-butyl 4-[3-(6-amino-2-methoxypyridin-3-yl)-3-oxopropyl]piperidine-1-carboxylate
• CAS: 557106-91-9
• 化学式: C₁₉H₂₉N₃O₄
• 分子量: 363.457
• InChiKey: NFYGSCKAPQLUDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  94.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl 4-{3-[6-amino-2-(methyloxy)-3-pyridinyl]-3-oxopropyl}-1-piperidinecarboxylate 生成 1-(6-amino-2-methoxy-3-pyridinyl)-3-(4-piperidinyl)-1-propanone
  参考文献：
  名称：

  Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators

  摘要：

  本发明提供了式(I)和(II)的化合物：1或其药学上可接受的酯和药学上可接受的盐：其中，R1是氢或卤素；R2和R3分别是氢或C1-6烷基；R4和R5分别是氢或C1-6烷基；R6是氢、C1-12烷基、C1-6烷氧基(C1-6)烷基或C1-12烷基，其被选自C3-8环烷基、芳基、杂芳基和杂环的最多3个取代基取代；R7和R8是氢或一起形成具有一个或两个碳原子的烷基链；R9是C1-6烷基或C3-8环烷基；R10是C1-6烷基或NR11R12；L是(CR11R12)或NR11；M是NR11或(CR11R12)n；R11和R12分别是氢或C1-6烷基；n是0到5的整数；m是0到2的整数；所述的杂环、芳基和杂芳基未取代或被至少一个取代基所取代，所述取代基被选自卤素和C1-6烷基；但当R9是C1-6烷基时，L不是NR11。这些化合物具有5-HT4受体结合活性，因此在哺乳动物，尤其是人类的治疗胃食管反流病、非溃疡性消化不良、肠易激综合征等方面是有用的。本发明还提供了包含上述化合物的制药组合物。

  公开号：

  US20030207875A1
• 作为产物：
  描述：

  1,1-dimethylethyl 4-(3-{6-[(2,2-dimethylpropanoyl)amino]-2-fluoro-3-pyridinyl}-3-oxopropyl)-1-piperidinecarboxylate 在 potassium tert-butylate 作用下， 以 甲醇 为溶剂， 以300 mg (100%)的产率得到1,1-dimethylethyl 4-{3-[6-amino-2-(methyloxy)-3-pyridinyl]-3-oxopropyl}-1-piperidinecarboxylate
  参考文献：
  名称：

  Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators

  摘要：

  本发明提供了式(I)和(II)的化合物：1或其药学上可接受的酯和药学上可接受的盐：其中，R1是氢或卤素；R2和R3分别是氢或C1-6烷基；R4和R5分别是氢或C1-6烷基；R6是氢、C1-12烷基、C1-6烷氧基(C1-6)烷基或C1-12烷基，其被选自C3-8环烷基、芳基、杂芳基和杂环的最多3个取代基取代；R7和R8是氢或一起形成具有一个或两个碳原子的烷基链；R9是C1-6烷基或C3-8环烷基；R10是C1-6烷基或NR11R12；L是(CR11R12)或NR11；M是NR11或(CR11R12)n；R11和R12分别是氢或C1-6烷基；n是0到5的整数；m是0到2的整数；所述的杂环、芳基和杂芳基未取代或被至少一个取代基所取代，所述取代基被选自卤素和C1-6烷基；但当R9是C1-6烷基时，L不是NR11。这些化合物具有5-HT4受体结合活性，因此在哺乳动物，尤其是人类的治疗胃食管反流病、非溃疡性消化不良、肠易激综合征等方面是有用的。本发明还提供了包含上述化合物的制药组合物。

  公开号：

  US20030207875A1

文献信息

• US6979690B2
  申请人：——

  公开号：US6979690B2

  公开（公告）日：2005-12-27
• [EN] OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS<br/>[FR] COMPOSES OXO OU OXY-PYRIDINE UTILISES COMME MODULATEURS DU RECEPTEUR 5-HT4
  申请人：PFIZER PHARMA

  公开号：WO2003057688A2

  公开（公告）日：2003-07-17

  This invention provides compounds of the formula (I) and (II) or the phannaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R1 is hydrogen or halo; R?2 and R3¿ are independently hydrogen or C¿1-6? alkyl; R?4 and R5¿ are independently hydrogen or C¿1-6? alkyl; R?6¿ is hydrogen, C ¿l-12? alkyl, C 1-6 alkoxy (C1-6)alkyl or C1-12 alkyl substituted by up to 3 substituents selected from the groups consisting of C3-8 cycloalkyl, aryl, heteroaryl and heterocyclic; R?7 and R8¿ are hydrogen or taken together may form alkylene chain having one or two carbon atoms; R9 is C¿1-6? alkyl or C3-8 cycloalkyl; R?10¿ is C¿1-6? alkyl or NR?11R12¿; L is (CR11R12)n or NR11 ; M is NR?11 or (CR11R12)n ; R11 and R12¿ are independently hydrogen or C¿1-6? alkyl; n is an integer from 0 to 5; and. m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and C1-6 alkyl; with the proviso that when R?9¿ is C¿1-6? alkyl, L is not NR?11¿. These compounds have 5-HT¿4? receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.
• Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators
  申请人：——

  公开号：US20030207875A1

  公开（公告）日：2003-11-06

  This invention provides compounds of the formula (I) and (II): 1 or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R 1 is hydrogen or halo; R 2 and R 3 are independently hydrogen or C 1-6 alkyl; R 4 and R 5 are independently hydrogen or C 1-6 alkyl; R 6 is hydrogen, C 1-12 alkyl, C 1-6 alkoxy (C 1-6 )alkyl or C 1-12 alkyl substituted by up to 3 substituents selected from the groups consisting of C 3-8 cycloalkyl, aryl, heteroaryl and heterocyclic; R 7 and R 8 are hydrogen or taken together may form alkylene chain having one or two carbon atoms; R 9 is C 1-6 alkyl or C 3-8 cycloalkyl; R 10 is C 1-6 alkyl or NR 11 R 12 ; L is (CR 11 R 12 ) n or NR 11 ; M is NR 11 or (CR 11 R 12 ) n ; R 11 and R 12 are independently hydrogen or C 1-6 alkyl; n is an integer from 0 to 5; and m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and C 1-6 alkyl; with the proviso that when R 9 is C 1-6 alkyl, L is not NR 11 . These compounds have 5-HT 4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了式(I)和(II)的化合物：1或其药学上可接受的酯和药学上可接受的盐：其中，R1是氢或卤素；R2和R3分别是氢或C1-6烷基；R4和R5分别是氢或C1-6烷基；R6是氢、C1-12烷基、C1-6烷氧基(C1-6)烷基或C1-12烷基，其被选自C3-8环烷基、芳基、杂芳基和杂环的最多3个取代基取代；R7和R8是氢或一起形成具有一个或两个碳原子的烷基链；R9是C1-6烷基或C3-8环烷基；R10是C1-6烷基或NR11R12；L是(CR11R12)或NR11；M是NR11或(CR11R12)n；R11和R12分别是氢或C1-6烷基；n是0到5的整数；m是0到2的整数；所述的杂环、芳基和杂芳基未取代或被至少一个取代基所取代，所述取代基被选自卤素和C1-6烷基；但当R9是C1-6烷基时，L不是NR11。这些化合物具有5-HT4受体结合活性，因此在哺乳动物，尤其是人类的治疗胃食管反流病、非溃疡性消化不良、肠易激综合征等方面是有用的。本发明还提供了包含上述化合物的制药组合物。